These results suggest that a combination of early IFN‐α/β and anti‐PD‐1 antibody treatments may not reduce parasitemia levels and improve mouse survival rates, even though late IL‐6 inhibits T cell immunity. This evidence concerns the gene PDCD1 and parasitic infectious disease.